Boston Scientific price target raised to $85 from $80 at Mizuho

Mizuho raised the firm’s price target on Boston Scientific to $85 from $80 and keeps a Buy rating on the shares. The analyst increased estimates post the Q1 report saying Farapulse is still in early innings of its U.S. launch and Watchman is well positioned for label expansions.